Healthcare and Medical

home | healthcare and medical | company profile

£265.00
Report Delivery: Via Email
Alerts
Change Currency EuroUSDGBP

Poniard Pharmaceuticals Inc - Premium Company Profile (Datamonitor)

  • Market: Healthcare and Medical
  • Published Date: 22/04/2008
  • Report Title: Poniard Pharmaceuticals Inc - Premium Company Profile
  • Table of Contents: View Table of Contents
  • Report Type: Company Profile
  • Country: Global
  • Number of Pages: 41
Introduction

Poniard Pharmaceuticals, formerly known as NeoRx Corporation, is a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapy products. The company’s lead product candidate, Picoplatin, is currently in Phase III clinical development for small cell lung cancer and offers a huge opportunity for the company to achieve its first commercial success.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    The company’s product pipeline includes single product, Picoplatin, a new generation cytotoxic platinum compound that provides a differentiated spectrum of activity and an improved safety profile. Picoplatin is being developed for small cell lung cancer (Phase III), colorectal cancer (Phase II), and prostate cancer (Phase II).

    The company does not have any significant ongoing revenue sources till date. On occasion, the company derives revenues from the sale or licensing of its patented technologies and from government grants.

    The company’s total revenues decreased from $11.1 million in 2002 to absolute zero in 2006. For the fiscal 2006, the company did not recognize any revenues due to non-recognition of any royalties for licensed intellectual property as recognized in 2004 and 2005 from Boston Scientific.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
  • £265.00   Share Report
     
    Alerts  

    Purchase Information

    There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.

    Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.

    Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.

    Worldpay Logo
    Chancy Currency EUR USD GBP
    Customer Area
    English Italian Spanish French German Russian Chinese Arabic